Loading clinical trials...
Loading clinical trials...
The primary purpose of this study is to assess the safety and efficacy of repeated subcutaneous (SC) injections of KRN23 in adult subjects with X-Linked Hypophosphatemia (XLH).
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Kyowa Kirin Co., Ltd.
Collaborators
NCT03745521 · X-Linked Hypophosphatemia
NCT03775187 · X-linked Hypophosphatemia, Tumor-Induced Osteomalacia
NCT04188964 · X-linked Hypophosphatemia (XLH)
NCT02915705 · X-Linked Hypophosphatemia
NCT04842032 · X-linked Hypophosphatemia (XLH)
University of California San Francisco
San Francisco, California
Yale University School of Medicine
New Haven, Connecticut
Clinical Research Center, Indiana University School of Medicine
Indianapolis, Indiana
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions